This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Senvelgo is the first liquid once-daily, orally administered prescription medication to improve glycemic control in cats with diabetes mellitus
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
Subscribe To Our Newsletter & Stay Updated
